Variants of Concern
The WHO classifies variants as Variants of Concern (VOC), Variants of Interest (VOI), or Variants Under Monitoring (VUM).
| WHO Name | Lineage | First Detected | Characteristics | Notable Symptoms |
|---|---|---|---|---|
| Alpha | B.1.1.7 | UK, Sept. 2020 | ~50% more transmissible than original strain; N501Y spike mutation | Similar to original: fever, cough, fatigue, loss of smell/taste |
| Beta | B.1.351 | South Africa, May 2020 | Partial resistance to some early vaccine-induced antibodies; E484K mutation | Similar to original; more severe disease in some cohorts |
| Gamma | P.1 | Brazil, Nov. 2020 | Multiple convergent mutations with Beta; K417T, E484K, N501Y | Similar to original; linked to reinfections |
| Delta | B.1.617.2 | India, Oct. 2020 | ~2× more transmissible than original; higher hospitalization rate; P681R mutation | Headache, sore throat, runny nose more prominent; loss of smell/taste less common |
| Omicron | B.1.1.529 | South Africa/Botswana, Nov. 2021 | 30+ mutations in spike protein; highest transmissibility; significant immune evasion; generally less severe than Delta per infection | Sore throat, runny nose, fatigue, headache; lower rates of loss of smell/taste; higher reinfection rate |
| Omicron subvariants | BA.2, BA.4/5, XBB, JN.1, KP.2+ | 2022–2025 | Progressive immune evasion with each generation; dominant strains rotate seasonally | Similar to Omicron; increased propensity for upper respiratory vs. lower lung disease |
How Variants Emerge and Why It Matters
SARS-CoV-2 is a positive-sense RNA virus, and RNA viruses replicate without the proofreading machinery that DNA viruses use to catch copying errors. The result is a high mutation rate — on the order of roughly one to two mutations per genome copy per replication cycle. Most of those changes are neutral or actively deleterious to the virus. Occasionally, however, a mutation lands in a functionally important region, such as the receptor-binding domain of the spike protein, and confers a replication or transmission advantage. When that happens in an environment with sufficient host-to-host spread, natural selection does the rest: the fitter variant outcompetes existing strains and, within weeks to months, becomes dominant.
The Alpha variant (B.1.1.7), first detected in the United Kingdom in September 2020, illustrates how rapidly this process can unfold. The N501Y mutation in its spike protein increased binding affinity to the human ACE2 receptor, making it roughly 50% more transmissible than the ancestral strain — as reflected in the table above. It reached majority prevalence in the UK within about two months of first detection and spread globally before any targeted public-health countermeasures specific to it could be deployed. Delta (B.1.617.2), which emerged in India in late 2020, went further: the P681R mutation it carried, also noted in the table, contributed to roughly double the transmissibility of the original strain and increased hospitalization risk compared to Alpha, making it the most clinically severe dominant variant until Omicron displaced it.
The Omicron variant (B.1.1.529), first reported in South Africa and Botswana in November 2021, represented a qualitative shift. With 30-plus mutations in its spike protein — many clustered in the receptor-binding domain and in sites targeted by vaccine-induced antibodies — Omicron was able to reinfect individuals who had prior immunity from infection, vaccination, or both. The WHO's classification as a Variant of Concern (VOC) reflects a formal risk assessment across transmissibility, disease severity, immune evasion, and the potential to undermine diagnostics or countermeasures. As the table shows, Omicron's subvariants (BA.2, BA.4/5, XBB, JN.1, KP.2 and beyond) have continued to accumulate immune-evasion mutations, rotating seasonally as population immunity to preceding subvariants builds and creating new dominant strains through 2022–2025.
The practical implication of this evolutionary pattern is that variant surveillance is not a one-time exercise. Updated vaccines formulated against currently circulating strains offer stronger protection against infection than older formulations targeting earlier versions of the spike protein — a principle analogous to the annual influenza vaccine update. The WHO's formal classification system (VOC, Variants of Interest, Variants Under Monitoring) provides a continuously updated public view of risk levels. For the current authoritative list, see the WHO variant tracking page and the CDC variant surveillance page. This is informational context, not medical advice — consult a healthcare provider for vaccination guidance specific to your situation.
